For these reasons, CBL-B blockade might increase T and NK cell response against cancer, including RS, and a first-in-human phase I trial, which includes DLBCL-type RS patients treated with the CBL-B inhibitor NX-1607 has been started [90]. Here, CBLB is linked to cancer.